Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8668387 | Journal of Clinical Lipidology | 2018 | 11 Pages |
Abstract
We report the case of a patient with probable heterozygous familial hypercholesterolemia and mitotane-induced resistant hypercholesterolemia, despite combination therapy with rosuvastatin and ezetimibe. The patient was managed with the addition of evolocumab. Use of a proprotein convertase subtilisin-kexin type 9 inhibitor, should be considered in patients who develop mitotane-related hypercholesterolemia that cannot be managed with conventional lipid-lowering treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Efthymia D. MD, MSc, Evangelos MD, PhD, FASA, FRSH, Zoe MD, Stelios MD, PhD, MRCP,